Union adds to company’s goal of reaching net-zero emissions by 2045.
Almac Group, a contract development and manufacturing organization (CDMO), announced it has officially joined the Science Based Targets Initiative (SBTi), which advocates for the best practices in science-based target settings. The company credits this move as the latest step taken with the objective of reaching net zero emissions by 2045.
The collaboration, which is headed by CDP, the United Nations Global Compact, the World Resources Institute (WRI), and the Worldwide Fund for Nature (WWF), is one of multiple steps Almac Group has taken to reach net zero. Other efforts include the expansion of accreditations with the International Standard Organization (ISO), accepted as the gold standard in health, safety, and environmental activity.
“Developing science-based targets for the reduction of greenhouse gas emissions is a crucial next step and demonstrates the commitment to our environmental responsibilities at Almac,” said Niall Harkin, executive director, Almac Group. “At Almac, we see transparency and alignment to internationally recognized standards as essential in demonstrating our commitment to making a measurable and positive impact on our planet.Signing up to SBTi, coupled with our latest ISO certifications represent an essential part of Almac’s plan to reach net-zero by 2045 and we are proud to mark these milestones in our progress.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.